Meta-analysis of efficacy and safety of Xinmailong Injection in treatment of heart failure after acute myocardial infarction.
10.19540/j.cnki.cjcmm.20200602.501
- Author:
Xin-di CHANG
1
;
Jing-Jing WEI
1
;
Xuan-Xuan HAO
1
;
Bin LI
2
;
Rui YU
2
;
Yong-Xia WANG
2
;
Ming-Jun ZHU
2
Author Information
1. Henan University of Traditional Chinese Medicine Zhengzhou 450000,China.
2. the First Affiliated Hospital of Henan University of Traditional Chinese Medicine Zhengzhou 450000,China.
- Publication Type:Meta-Analysis
- Keywords:
Meta-analysis;
Xinmailong Injection;
acute myocardial infarction;
heart failure;
systematic review
- MeSH:
Drugs, Chinese Herbal/therapeutic use*;
Heart Failure/drug therapy*;
Humans;
Injections;
Myocardial Infarction/drug therapy*
- From:
China Journal of Chinese Materia Medica
2021;46(5):1250-1259
- CountryChina
- Language:Chinese
-
Abstract:
To systematically evaluate the clinical efficacy and safety of Xinmailong Injection in the treatment of heart failure after acute myocardial infarction. Seven Chinese and English databases, namely CNKI, VIP, Wanfang, SinoMed and PubMed, EMbase, Cochrane Library, were retrieved from the establishment of the database to March 2020. Randomized controlled trials for Xinmailong Injection in the treatment of heart failure after acute myocardial infarction were screened out. Cochrane collaboration network bias risk assessment tool was used to evaluate the literature quality of the studies included, and RevMan 5.3 software was used for Meta-analysis. A total of 926 relevant literatures were retrieved, and 12 studies were finally included, involving 972 patients, including 486 patients in the treatment group and 486 patients in the control group. The quality of the literatures included was generally low. The results of Meta-analysis showed that Xinmailong Injection combined with Western medicine could decrease the levels of BNP(SMD=-5.90, 95%CI[-8.45,-3.36], P<0.000 01) and NT-proBNP(SMD=-2.28, 95%CI[-3.13,-1.43], P<0.000 01) and decrease the levels of cTnI(SMD=-2.91, 95%CI[-4.21,-1.60], P<0.000 1), increase LVEF(MD=4.67, 95%CI[4.19, 5.16], P<0.000 01), increased 6 MWT(MD=73.90, 95%CI[67.51, 80.28], P<0.000 01], decreased LVEDD(MD=-5.46, 95%CI[-9.66,-1.25], P=0.01), reduce the level of serum inflammatory factor(hs-CRP, CRP, IL-6). In terms of safety, less adverse reactions occurred in the study, with no impact on the treatment. The results showed that clinical use of Xinmailong Injection combined with Western medicine in the treatment of heart failure after acute myocardial infarction can further alleviate clinical symptoms and relevant indexes, with less adverse reactions. However, due to the limitations in quantity and quality of the clinical studies included, the positive results can only be used as a hint and reference for clinical diagnosis and treatment, and more high-quality studies are needed to further confirm its efficacy.
